Tilomisole

Tilomisole
Names
	Preferred IUPAC name [3-(4-Chlorophenyl)[1,3]thiazolo[3,2-a] [1,3]benzimidazol-2-yl]acetic acid
Identifiers
CAS Number	58433-11-7;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2104737;
ChemSpider	38987;
KEGG	D06148;
PubChem CID	42747;
UNII	651G60U372 ;
CompTox Dashboard (EPA)	DTXSID40207137 ;
	InChI InChI=1S/C17H11ClN2O2S/c18-11-7-5-10(6-8-11)16-14(9-15(21)22)23-17-19-12-3-1-2-4-13(12)20(16)17/h1-8H,9H2,(H,21,22);
	SMILES Clc4ccc(c1c(sc2nc3ccccc3n12)CC(=O)O)cc4;
Properties
Chemical formula	C17H11ClN2O2S
Molar mass	342.80
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Tilomisole (WY-18,251) is an experimental drug which acts as an immunomodulator and has been studied for the treatment of some forms of cancer.^[1]^[2]

It can also be seen to contain the arylacetic acid moiety that is endemic to many NSAIDs, e.g. ibufenac.^{[citation needed]}

References

^ Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology. 2 (4): 491–508. doi:10.3109/08923978009026408. PMID 6970786.
^ Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy. 4 (1): 10–4. PMID 1385709.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[pmid6970786-1] Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology. 2 (4): 491–508. doi:10.3109/08923978009026408. PMID 6970786.

[pmid1385709-2] Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy. 4 (1): 10–4. PMID 1385709.

[1]

[2]